Home/Xenon Pharmaceuticals/Dr. Elizabeth (Liz) Garofalo
DE

Dr. Elizabeth (Liz) Garofalo

Executive Vice President, Head of Clinical Development

Xenon Pharmaceuticals

Therapeutic Areas

Xenon Pharmaceuticals Pipeline

DrugIndicationPhase
XEN1101Major Depressive Disorder (MDD)Phase 3
XEN496 (NBI-921352)KCNQ2 Developmental and Epileptic EncephalopathyPhase 2/3
XEN053Undisclosed TargetPreclinical